UTHealth Houston-developed cancer therapy platform takes major step toward clinical translation
CrossBridge Bio, a biotechnology company developing next-generation antibody-drug conjugates based on discoveries by researchers at UTHealth Houston, is taking a major step toward clinical translation after being acquired by Eli Lilly. The dual-payload antibody-drug conjugate technology was originally created by…
An lab discovers novel nasal treatment for influenza
New data from researchers at the Brown Foundation Institute of Molecular Medicine exploring novel therapeutic approaches to treating Influenza A viruses has been published in Nature Communications. The paper, titled “An intranasally administered IgM protects against antigenically distinct subtypes of influenza…
University researchers receive more than $5 million from CPRIT
Three UTHealth Houston researchers, including two from McGovern Medical School, received more than $5 million in funding from the Cancer Prevention and Research Institute of Texas (CPRIT), furthering the state’s mission to prevent and treat cancer through innovative science and…
An wins ASPET scientific achievement award
The American Society for Pharmacology and Experimental Therapeutics (ASPET) has named Zhiqiang An, PhD, professor and Robert A. Welch Distinguished University Chair in Chemistry and vice president of Drug Discovery, as the winner of its 2024 Scientific Achievement Award in…
An named UTHealth Houston’s first vice president of drug discovery
Zhiqiang An, PhD, has been named UTHealth Houston’s first vice president of drug discovery. In this new role, An will work in close collaboration with researchers across campus, as well as the Office of Technology Management, Academic and Faculty Affairs,…